Epoxyeicosatrienoic acids (EETs) are small molecules produced by cytochrome P450 epoxygenases. They are lipid mediators that act as autocrine or paracrine factors to regulate inflammation and vascular tone. As a result, drugs that raise EET levels are in clinical trials for the treatment of hypertension and many other diseases. However, despite their pleiotropic effects on cells, little is known about the role of these epoxyeicosanoids in cancer. Here, using genetic and pharmacological manipulation of endogenous EET levels, we demonstrate that EETs are critical for primary tumor growth and metastasis in a variety of mouse models of cancer. Remarkably, we found that EETs stimulated extensive multiorgan metastasis and escape from tumor dormancy in several tumor models. This systemic metastasis was not caused by excessive primary tumor growth but depended on endothelium-derived EETs at the site of metastasis. Administration of synthetic EETs recapitulated these results, while EET antagonists suppressed tumor growth and metastasis, demonstrating in vivo that pharmacological modulation of EETs can affect cancer growth. Furthermore, inhibitors of soluble epoxide hydrolase (sEH), the enzyme that metabolizes EETs, elevated endogenous EET levels and promoted primary tumor growth and metastasis. Thus, our data indicate a central role for EETs in tumorigenesis, offering a mechanistic link between lipid signaling and cancer and emphasizing the critical importance of considering possible effects of EET-modulating drugs on cancer.
Dipak Panigrahy, Matthew L. Edin, Craig R. Lee, Sui Huang, Diane R. Bielenberg, Catherine E. Butterfield, Carmen M. Barnés, Akiko Mammoto, Tadanori Mammoto, Ayala Luria, Ofra Benny, Deviney M. Chaponis, Andrew C. Dudley, Emily R. Greene, Jo-Anne Vergilio, Giorgio Pietramaggiori, Sandra S. Scherer-Pietramaggiori, Sarah M. Short, Meetu Seth, Fred B. Lih, Kenneth B. Tomer, Jun Yang, Reto A. Schwendener, Bruce D. Hammock, John R. Falck, Vijaya L. Manthati, Donald E. Ingber, Arja Kaipainen, Patricia A. D’Amore, Mark W. Kieran, Darryl C. Zeldin
Title and authors | Publication | Year |
---|---|---|
Pre-operative stimulation of resolution and inflammation blockade eradicates micrometastases
Dipak Panigrahy, Allison Gartung, Jun Yang, Haixia Yang, Molly M. Gilligan, Megan L. Sulciner, Swati S Bhasin, Diane R. Bielenberg, Jaimie Chang, Birgitta A. Schmidt, Julia Piwowarski, Anna Fishbein, Dulce Soler-Ferran, Matthew A. Sparks, Steven J. Staffa, Vidula Sukhatme, Bruce D. Hammock, Mark W. Kieran, Sui Huang, Manoj Bhasin, Charles N. Serhan, Vikas P. Sukhatme |
Journal of Clinical Investigation | 2019 |
New Lipid Mediators in Retinal Angiogenesis and Retinopathy
I Fleming |
Frontiers in pharmacology | 2019 |
Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion
P Kreuzaler, Y Panina, J Segal, M Yuneva |
Molecular Metabolism | 2019 |
Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer
MK Apaya, JY Shiau, GS Liao, YJ Liang, CW Chen, HC Yang, CH Chu, JC Yu, LF Shyur |
Journal of Experimental & Clinical Cancer Research | 2019 |
Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications
F Rossari, C Zucchinetti, G Buda, E Orciuolo |
Cellular Oncology | 2019 |
Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future
B Park, TW Corson |
Frontiers in pharmacology | 2019 |
Aspirin-triggered proresolving mediators stimulate resolution in cancer
MM Gilligan, A Gartung, ML Sulciner, PC Norris, VP Sukhatme, DR Bielenberg, S Huang, MW Kieran, CN Serhan, D Panigrahy |
Proceedings of the National Academy of Sciences | 2019 |
Cancer and Microenvironment Plasticity: Double-Edged Swords in Metastasis
X Zhuang, H Zhang, G Hu |
Trends in Pharmacological Sciences | 2019 |
Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis
W Wang, J Yang, ML Edin, Y Wang, Y Luo, D Wan, H Yang, CQ Song, W Xue, KZ Sanidad, M Song, HA Bisbee, JA Bradbury, G Nan, J Zhang, PB Shih, KS Lee, LM Minter, D Kim, H Xiao, JY Liu, BD Hammock, DC Zeldin, G Zhang |
Cancer research | 2019 |
Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis
RD Jones, J Liao, X Tong, D Xu, L Sun, H Li, GY Yang |
Frontiers in pharmacology | 2019 |
Cancer cell population growth kinetics at low densities deviate from the exponential growth model and suggest an Allee effect
KE Johnson, G Howard, W Mo, MK Strasser, EA Lima, S Huang, A Brock, AF Read |
PLoS Biology | 2019 |
Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction
Y Savina, T Duflot, F Bounoure, S Kotzki, PA Thiebaut, PA Serreau, M Skiba, JM Picquenot, M Cornic, C Morisseau, B Hammock, L Imbert, JL Cracowski, V Richard, M Roustit, J Bellien |
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease | 2019 |
Inhibition of Pancreatic Carcinoma Growth Through Enhancing ω-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase
XIA R, SUN L, LIAO J, LI H, YOU X, XU D, YANG J, HWANG SH, JONES RD, HAMMOCK B, YANG GY |
Anticancer research | 2019 |
Cytochrome P450 monooxygenase/soluble epoxide hydrolase-mediated eicosanoid pathway in colorectal cancer and obesity-associated colorectal cancer.
Zhang J, Sanidad KZ, Zhang G |
Oncoscience | 2019 |